Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01203787 · ClinicalTrials.gov registry record · Phase 4
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
A Phase 4 study of Hepatocellular Carcinoma, sponsored by University of Florida.
- Completed
- Registry status
- Phase 4
- Development phase
- 120
- Enrollment target
- 9
- Study locations
NCT01203787 is a Phase 4 study of Hepatocellular Carcinoma that has completed, run by University of Florida. The registered enrollment target is 120 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (53% lower). The trial reports 9 study locations across 5 states.
The verdict
NCT01203787, a Phase 4 study of Hepatocellular Carcinoma, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 120 participants
- Enrollment target
- 9
- Study locations
Study Summary
Open-label study to evaluate the safety and tolerability of Sorafenib dose ramp-up (starting at a lower dose and then gradually increasing the dose) versus standard Sorafenib dosing in subjects with unresectable and/or metastatic hepatocellular carcinoma.
Conditions Studied
Interventions
- DRUG Sorafenib Standard Dosing Regimen
- DRUG Sorafenib Ramp-Up Regimen
Study Locations (9)
Florida
- University of Florida Hepatology - Gainesville
- Mayo Clinic - Jacksonville
- Florida Hospital Transplant Center - Orlando
- Tampa General Hospital - Tampa
Texas
- University of Texas Health Science Center Houston - Houston
- Brooke Army Medical Center - San Antonio
Illinois
- Loyola University Medical Center - Maywood
Michigan
- Henry Ford Health System - Detroit
Pennsylvania
- Drexel University College of Medicine - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2010-12 |
| Est. Completion | 2014-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01203787
The ClinicalTrials.gov registry entry for NCT01203787 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (53% lower). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Sorafenib Standard Dosing Regimen is the first listed.
NCT01203787 reports 9 study locations spanning 5 distinct geographic areas - top geographies include Florida, Texas, Illinois.
Frequently Asked Questions
What is clinical trial NCT01203787 about?
NCT01203787 is a clinical study titled "Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)". Open-label study to evaluate the safety and tolerability of Sorafenib dose ramp-up (starting at a lower dose and then gradually increasing the dose) versus standard Sorafenib dosing in subjects with unresectable and/or metastatic hepatocellular carcinoma.
What is the current status of trial NCT01203787?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 120 participants. The study started on 2010-12. Estimated completion is 2014-03.
What conditions does trial NCT01203787 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma.
What interventions are being tested in trial NCT01203787?
The interventions under investigation include: Sorafenib Standard Dosing Regimen (DRUG), Sorafenib Ramp-Up Regimen (DRUG).
Who is sponsoring clinical trial NCT01203787?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01203787 being conducted?
This trial has 9 study locations across Florida, Illinois, Michigan, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant
RECRUITING · Phase 4
-
Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria
RECRUITING · Phase 4
-
Molecular Basis of Pediatric Liver Cancer
RECRUITING
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Targeted Navigation in Hepatocellular Carcinoma (HCC)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.